Newest Oligo BioAnalysis Methods
Oligos, Oligos, Oligos!
Oligonucleotide therapeutics and reagents are everywhere. They are helping the world address previously untreatable diseases, and they are also being used in new ways to sensitively quantify and sequence important translational research samples. Whether it be a CRISPR guide RNA, lipid conjugated anti-sense oligonucleotide, or a specially modified assay probe, these molecules must be tested to ensure they have the right sequence, pinpoint-specific modifications, conjugate moieties and purities. And when dosed as a therapeutic, they need to be carefully quantified to confirm pharmacokinetic models.
Join the Waters Chromatography and LC-MS Team and their collaborators from MRIGlobal, Regeneron, and Acuitas Therapeutics in this special episodic, 3 week webinar series to learn more about the science of oligos and the power of LC-based approaches to analyze them.
EPISODE 2
Part 1: Bioanalytical Protocols for Challenging Human Plasma and Brain Tissue Samples: Enhancing Recovery of Oligonucleotides Across Diverse Matrix Types
Developing bioanalytical sample preparation and LC-MS analytical methods for oligonucleotides, in support of ADME/DMPK research, poses significant challenges due to their structural diversity, low circulating concentration, and the complexity of the various biological matrices (e.g., plasma, urine and organ tissues).
Presenter: Mary Trudeau (Consulting Scientist, Cell and Gene Therapy Consumables, Waters Corporation)
Following a successful career in pharma with Pfizer, Mary joined Waters in 2011. She is responsible for developing and optimizing analytical methods and workflows in support of large molecule bioanalytical ADME/DMPK. Her most recent focus has been developing robust sample prep and LC-MS workflows for oligonucleotides.
Part 2: Progressing Mass Spectrometry to Bioanalysis of siRNA therapeutics
The COVID-19 pandemic has catalyzed a surge in the development of oligonucleotide therapeutics, driven by their potential to treat diseases once considered incurable. The success of mRNA vaccines has further fueled interest, leading to a proliferation of diverse oligonucleotide-based therapeutic modalities. Each of these new modalities demands rigorous analytical characterization, akin to the established methods for protein and peptide-based drugs. However, standardized methods for these novel oligonucleotide therapies are still in their infancy.
Presenter: Sam Sarni (Senior Scientist, Analytical Chemistry Group, Regeneron Pharmaceuticals)
Sam Sarni earned her Ph.D. in Biochemistry from The Ohio State University and a B.Sc. in Chemistry from Southern Oregon University. Dr. Sarni specializes in developing LC-MS based analytical methods to support novel therapeutics and monoclonal antibody-based proteins. Her current research focus is on siRNA bioanalysis, where she performs LC-MS data analysis to elucidate the quality attributes of siRNA. Dr. Sarni leads R&D activities to deepen the understanding of siRNA therapeutics
